Abstracts tagged "Systemic lupus erythematosus (SLE)"

Abstract Number: 0589 • ACR Convergence 2023
A Comparative Evaluation of IgA2 Anti-dsDNA Antibodies and Clinical Outcome in Two Clinical Trials of Belimumab After Rituximab in SLE
Muhammad RA Shipa¹, Daniel McCluskey¹, Laura Cooney² and Michael Ehrenstein¹, ¹University College London, London, United Kingdom, ²Immune Tolerance Network, Seattle, WA
Background/Purpose: We have shown that serum IgA2 anti-dsDNA antibody levels is a biomarker of response to belimumab after rituximab in SLE (BEAT-lupus trial) (1). We…
Abstract Number: 0608 • ACR Convergence 2023
Efficacy of Cenerimod in Patients with High IFN-1 Gene Expression Signature and High Anti-dsDNA Antibody Levels: Post-hoc Analysis from a Phase 2 Study
Anca Askanase¹, David D'Cruz², Kenneth Kalunian³, Joan Merrill⁴, Sandra Navarra⁵, Clélia Cahuzac⁶, Peter Cornelisse⁶, Daniel Strasser⁶, Luba Trokan⁷ and Ouali Berkani⁸, ¹Columbia University Medical Center, New York, NY, ²Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom, ³University of California San Diego, La Jolla, CA, ⁴Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁵University of Santo Tomas Hospital, Joint and Bone Center, Manila, Philippines, ⁶Idorsia Pharmaceuticals Ltd., Allschwil, Switzerland, ⁷Idorsia Pharmaceuticals Ltd. at time of data generation, Allschwil, Switzerland, ⁸IDORSIA, Allschwil, Switzerland
Background/Purpose: Cenerimod is an orally active, selective sphingosine 1-phosphate (S1P) 1 receptor modulator under investigation for the treatment of systemic lupus erythematosus (SLE). In the…
Abstract Number: 0847 • ACR Convergence 2023
Development of an IFN 5-Gene Signature Score to Identify IFN-high and IFN-low Subsets and as a Pharmacodynamic Biomarker for Deucravacitinib Treatment in a Phase 2 Trial in Patients with Systemic Lupus Erythematosus
Chun Wu¹, Yanhua Hu¹, Mary K. Crow², Amit Saxena³, Cristina Arriens⁴, Coburn Hobar¹, Adrian Coles⁵ and Ian M. Catlett⁶, ¹Bristol Myers Squibb, Princeton, NJ, ²Hospital for Special Surgery, New York, NY, ³NYU Langone, New York, NY, ⁴Oklahoma Medical Research Foundation and University of Oklahoma Health Sciences Center, Department of Arthritis & Clinical Immunology, Oklahoma City, OK, ⁵Bristol Myers Squibb, Lawrenceville, NJ, ⁶Bristol Myers Squibb, Pennington, NJ
Background/Purpose: Elevated IFN activity is observed in a subset of lupus subjects suggesting that those with higher levels of IRGs may benefit from interferon targeted…
Abstract Number: 0902 • ACR Convergence 2023
Neutrophils in Systemic Lupus Erythematosus Demonstrate Heterogeneity Based on Sex
William Ambler¹, Gustaf Wigerblad¹, Eduardo Patino-martinez¹, Shuichiro Nakabo¹, Norio Hanata¹, Stephen Brooks², Kan Jiang², Carmelo Carmona-Rivera¹ and Mariana Kaplan³, ¹Systemic Autoimmunity Branch, National Institute of Arthritis and Musculoskeletal and Skins Diseases, National Institutes of Health, Bethesda, MD, ²Biodata Mining and Discovery Section, National Institute of Arthritis and Musculoskeletal and Skins Diseases, National Institutes of Health, Bethesda, MD, ³Lupus Clinical Trials Unit, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health (NIH); Systemic Autoimmunity Branch, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health (NIH), Bethesda, MD
Background/Purpose: Sex differences in the immune system may contribute to o an increased incidence of autoimmunity in women and an increased susceptibility to infection and…
Abstract Number: 0919 • ACR Convergence 2023
Investigating the Role of Interferon in Promoting Flares of SLE at a Single Cell Level
Zoha Faheem¹, Giselle Boukhaled², Kieran Manion¹, Carolina Munoz-Grajales³, Carol Nassar¹, Michael Kim¹, Dafna Gladman⁴, Murray Urowitz⁵, Zahi Touma⁶, David Brooks² and Joan Wither⁷, ¹Schroeder Arthritis Institute, Krembil Research Institute, Toronto, ON, Canada, ²Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada, ³UHN/TWH, Toronto, ON, Canada, ⁴Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western Hospital, Department of Medicine, University of Toronto, Toronto, ON, Canada, ⁵Schroeder Arthritis Institute, Krembil Research Institute; University of Toronto Lupus Clinic; Division of Rheumatology, Toronto, ON, Canada, ⁶University of Toronto, Toronto, ON, Canada, ⁷University Health Network, Toronto, ON, Canada
Background/Purpose: Systemic lupus erythematosus (SLE) is a heterogeneous autoimmune disease with unpredictable flares interspersed with prolonged periods of disease quiescence. Interferon (IFN) is a hallmark…
Abstract Number: 1092 • ACR Convergence 2023
Improving Screening of Lupus Nephritis in Patients with Systemic Lupus Erythematous
Lilian Otalora Rojas¹, Gurjit S Kaeley² and Myint Thway³, ¹University of Florida, Ponte Vedra Beach, FL, ²University of Florida College of Medicine – Jacksonville, Ponte Vedra Beach, FL, ³UF Jacksonville, Ponte Vedra, FL
Background/Purpose: Nephritis remains one of the most devastating complications of Systemic lupus erythematosus (SLE). Lupus nephritis (LN) significantly reduces overall survival to approximately 88% at…
Abstract Number: 1244 • ACR Convergence 2023
Characterizing Lupus in African American Children in Southern United States
Anita Dhanrajani¹, Taylor Long², Spencer Hagwood², Cynthia Karlson² and Cali Foreman², ¹University of Mississippi Medical Center, New Orleans, LA, ²University of Mississippi Medical Center, Jackson, MS
Background/Purpose: African-American (AA) ethnicity is a known predisposing factor for childhood onset systemic lupus erythematosus (cSLE) and a predictor of poor outcomes. In addition to…
Abstract Number: 1445 • ACR Convergence 2023
SLESIS-R: An Improved Score for Prediction of Serious Infection in Patients with Systemic Lupus Erythematosus Based on the RELESSER Prospective Cohort
Iñigo Rúa-Figueroa¹, Maria Jesus Garcia de Yebenes², JULIA MARTINEZ BARRIO³, Maria Galindo-Izquierdo⁴, Jaime Calvo- Alén⁵, Antonio Fernandez-Nebro⁶, Raúl Menor-Almagro⁷, Eva Tomero Muriel⁸, Mercedes Freire González⁹, Clara Sanguesa Gomez¹⁰, Loreto Horcada¹¹, Ricardo Blanco¹², Esther Uriarte Isacelaya¹³, Maria J. García-Villanueva¹⁴, Javier Narvaez¹⁵, Jose Rosas¹⁶, Silvia Gómez-Sabater¹⁷, Clara Moriano Morales¹⁸, Jose Luis Andreu-Sánchez¹⁹, Vicente Torrente-Segarra²⁰, Elena Aurrecoechea Aguinaga²¹, Ana Pérez Gómez²², Javier Novoa Medina²³, Eva Salgado-Pérez²⁴, Nuria Lozano Rivas²⁵, Carlos Montilla-Morales²⁶, maria esther ruiz-lucea²⁷, Marta Arévalo Salaet²⁸, Carlota Iñíguez²⁹, Lorena Expósito³⁰, Mónica Ibáñez-Barceló³¹, Gema Bonilla³², Irene Carrión-Barberà³³, Celia Erausquin³⁴, Angela Pecondon-Español³⁵, Francisco Javier Toyos Sáenz de Miera³⁶, Tatiana Cobo³⁷, Alejandro Muñoz³⁸, Jorge Juan Fragio³⁹, Jose Eloy Oller⁴⁰, Beatriz Tejera Segura²³ and Jose-Maria Pego-Reigosa⁴¹, ¹Rheumatology, Hospital de Gran Canaria Doctor Negrin, Las Palmas de Gran Canaria, Spain, ²InMusc, Madrid, Spain, ³Rheumatology, Gregorio Marañon University Hospital, Madrid, Spain, ⁴Rheumatology, University Hospital of 12 de Octubre, Madrid, Spain, ⁵Rheumatology, Bioaraba Research Unit, Hospital Universitario Araba, Vitoria, Spain, ⁶Hospital Regional Universitario de Málaga, Malaga, Spain, ⁷Rheumatology, Hospital Jerez, Puerto De Santa María, Spain, ⁸Rheumatology, Hospital La Princesa, Madrid, Spain, ⁹Rheumatology department, Complexo Hospitalario Universitario A Coruña (CHUAC). Instituto de Investigación Biomédica A Coruña (INIBIC), A Coruña, Spain, ¹⁰Severo Ochoa Hospital, Madrid, Spain, ¹¹Hospital de Navarra, Pamplona, Spain, ¹²Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain, ¹³Rheumatology, University Hospital of Donosti, San Sebastián, Spain, ¹⁴Hospital Ramón y Cajal, Madrid, Spain, ¹⁵Hospital Universitario de Bellvitge, Barcelona, Spain, ¹⁶Hospital Marina Baixa, Alicante, Spain, ¹⁷Rheumatology Department, Dr. Balmis University General Hospital, Alicante. Institute for Health and Biomedical Research (ISABIAL), Alicante, Spain, ¹⁸Rheumatology, Hospital Universitario de León, León, Spain, ¹⁹Rheumatology, Hospital Universitario Puerta de Hierro, Majadahonda, Spain, ²⁰Department of Rheumatology, Hospital de Sant Joan Despí Moises Broggi,, Sant Joan Despí, Spain, ²¹Department of Rheumatology, Hospital Sierrallana, Torrelavega, Spain, ²²Rheumatology, Hospital Principe de Asturias, Alcalá de Henares, Spain, ²³Complejo Hospitalario Universitario Insular de Gran Canaria, Las Palmas de Gran Canaria, Spain, ²⁴Department of Rheumatology, University Hospital of Ourense, Ourense, Spain, ²⁵Department of Rheumatology, Hospital Clínico Universitario Virgen de la Arrixaca, Murcia, Spain, ²⁶Rheumatology, University Hospital of Salamanca, Salamanca, Spain, ²⁷Hospita de Basurto, Bilbao, Spain, ²⁸Rheumatology Department University Hospital Parc Taulí, Sabadell, Spain, ²⁹Hospital Lucus Augusti, Lugo, Spain, ³⁰Rheumatology Unit, Hospital Universitario de Canarias, San Cristóbal de La Laguna, Spain, ³¹Rheumatology, Hospital Universitari Son Llàtzer, Palma de Mallorca, Spain, ³²Department of Rheumatology, Hospital Clínico Universitario La Paz, Madrid, Spain, ³³Hospital del Mar, Barcelona, Spain, ³⁴Rheumatology Department Hospital Universitario de Gran Canaria Doctor Negrín, Las Palmas de Gran Canaria, Spain, ³⁵Hospital Miguel Servet, Zaragoza, Spain, ³⁶Hospital Virgen Macarena, Sevilla, Spain, ³⁷Department of Rheumatology, Hospital Universitario Infanta Sofía, Universidad Europea, Madrid, Spain, ³⁸Hospital universitario Virgen del Rocío, El Viso de Alcor, Spain, ³⁹Hospital General Universitario Valencia, Valencia, Spain, ⁴⁰Hospital Doctor Peset, Valencia, Spain, ⁴¹Rheumatology, Hospital do Meixoeiro, Vigo, Spain
Background/Purpose: Patients with systemic lupus erythematosus (SLE) have an increased risk of serious infections that varies with the severity of the disease, use of immunosuppressives,…
Abstract Number: 1462 • ACR Convergence 2023
Cardiovascular Damage in Systemic Lupus Erythematosus Occurs at Early Stages of the Disease. Chronological Analysis of Damage Accrual in a Large Cohort from the Spanish Society of Rheumatology Lupus Registry (RELESSER)
Sara garcia Perez¹, Jose-Maria Pego-Reigosa², Irene Altabás González¹, Norman Jiménez³, Victor Del campo Perez⁴, JULIA MARTINEZ BARRIO⁵, Maria Galindo-Izquierdo⁶, Jaime Calvo- Alén⁷, Esther Uriarte Isacelaya⁸, Eva Tomero Muriel⁹, Mercedes Freire González¹⁰, Victor Martinez-Taboada¹¹, Paloma Vela¹², Antonio Fernandez-Nebro¹³, Alejandro Olivé-Marqués¹⁴, Javier Narvaez¹⁵, Raúl Menor-Almagro¹⁶, Gregorio Santos Soler¹⁷, José Ángel Hernández Beriain¹⁸, Javier Manero ruiz¹⁹, Elena Aurrecoechea Aguinaga²⁰, Oihane Ibarguengoitia-Barrena²¹, Carlos Montilla-Morales²², Gema Bonilla²³, Vicente Torrente-Segarra²⁴, Ana Paula Cacheda²⁵, Maria J. García-Villanueva²⁶, Clara Moriano Morales²⁷, Concepción Fito Manteca²⁸, Cristina Bohórquez²⁹, Nuria Lozano Rivas³⁰ and Iñigo Rúa-Figueroa³¹, ¹Department of Rheumatology, University Hospital of Vigo. IRIDIS Group (Investigation in Rheumatology and Immune-Diseases), Vigo, Spain, ²Rheumatology, Hospital do Meixoeiro, Vigo, Spain, ³IIRIDIS (Investigation in Rheumatology and Immune-Mediated Diseases) Group, Galicia Sur Health Research Institute., Vigo, Spain, ⁴Department of Epidemiology, University Hospital of Vigo, IRIDIS Group (Investigation in Rheumatology and Immune-Diseases), Vigo, Spain, ⁵Rheumatology, Gregorio Marañon University Hospital, Madrid, Spain, ⁶Rheumatology, University Hospital of 12 de Octubre, Madrid, Spain, ⁷Rheumatology, Bioaraba Research Unit, Hospital Universitario Araba, Vitoria, Spain, ⁸Rheumatology, University Hospital of Donosti, San Sebastián, Spain, ⁹Rheumatology, Hospital La Princesa, Madrid, Spain, ¹⁰Rheumatology department, Complexo Hospitalario Universitario A Coruña (CHUAC). Instituto de Investigación Biomédica A Coruña (INIBIC), A Coruña, Spain, ¹¹Rheumatology, Hospital Marqués de Valdecilla, Santander, Spain, ¹²Department of Rheumatology, University Hospital of Alicante, Alicante, Spain, ¹³Hospital Regional Universitario de Málaga, Malaga, Spain, ¹⁴Department of Rheumatology, Hospital Germans Trias i Pujol, Badalona, Spain, ¹⁵Hospital Universitario de Bellvitge, Barcelona, Spain, ¹⁶Rheumatology, Hospital Jerez, Puerto De Santa María, Spain, ¹⁷Rheumatology, Hospital Marina Baixa Villajoyosa, Alicante, Spain, ¹⁸Rheumatology, Hospital Insular de Gran Canaria, Las Palmas de Gran Canaria, Spain, ¹⁹Department of Rheumatology, Hospital Universitario Miguel Servet, Zaragoza, Spain, ²⁰Department of Rheumatology, Hospital Sierrallana, Torrelavega, Spain, ²¹Galdakao-Usansolo University Hospital, Bilbao, Spain, ²²Rheumatology, University Hospital of Salamanca, Salamanca, Spain, ²³Department of Rheumatology, Hospital Clínico Universitario La Paz, Madrid, Spain, ²⁴Department of Rheumatology, Hospital de Sant Joan Despí Moises Broggi,, Sant Joan Despí, Spain, ²⁵Department of Rheumatology, Hospital Son Llatzer, Palma de Mallorca, Spain, ²⁶Hospital Ramón y Cajal, Madrid, Spain, ²⁷Rheumatology, Hospital Universitario de León, León, Spain, ²⁸Department of Rheumatology, University Hospital of Navarra, Pamplona, Spain, ²⁹Department of Rheumatology, University Hospital Príncipe de Asturias, Alcalá de Henares, Spain, ³⁰Department of Rheumatology, Hospital Clínico Universitario Virgen de la Arrixaca, Murcia, Spain, ³¹Rheumatology, Hospital de Gran Canaria Doctor Negrin, Las Palmas de Gran Canaria, Spain
Background/Purpose: Systemic Lupus Erythematosus (SLE) survival has improved during recent decades, so other outcomes like damage accrual become more relevant. Damage represents that clinical feature…
Abstract Number: 1478 • ACR Convergence 2023
Presentation and Outcomes of Posterior Reversible Encephalopathy Syndrome in Systemic Lupus Erythematosus: A Multicenter Cohort and a Systematic Literature Review
Alain Sanchez-Rodriguez¹, Mariana Gonzalez-Treviño¹, Hannah Langenfeld², Cynthia Crowson³, Maria Valenzuela-Almada⁴, Alejandro Rabinstein⁵, Larry J. Prokop⁶, Isabel Valenzuela-Almada⁷ and Ali Duarte-Garcia³, ¹Division of Rheumatology, Mayo Clinic, Rochester, MN, ²Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN, ³Mayo Clinic, Rochester, MN, ⁴Department of Pediatrics, Children’s National Medical Center, Washington, DC, ⁵Department of Neurology, Mayo Clinic, Rochester, MN, ⁶Mayo Clinic Libraries, Mayo Clinic, Rochester, MN, ⁷Division of Internal Medicine, Hospital Medica Sur, Mexico City, Mexico
Background/Purpose: To describe the clinical characteristics, therapies, and outcomes of patients with SLE and Posterior reversible encephalopathy syndrome (PRES). Methods: We performed a multicenter cohort…
Abstract Number: 1496 • ACR Convergence 2023
Clinical Safety and Efficacy Results from EQUALISE Type B: A Phase 1b Open-label Clinical Study of Itolizumab, a Novel anti-CD6 Therapy, in Subjects with Active Proliferative Lupus Nephritis
Kenneth Kalunian¹, Robert Levin², Sreejith Parameswaran³, nelson kopyt⁴, Stephen Connelly⁵, Eugene Sun⁵, Katie Kim⁵, maple fung⁵ and Manish Rathi⁶, ¹University of California San Diego, La Jolla, CA, ²South Florida University, Tampa, FL, ³JIPMER, New Delhi, India, ⁴LeHigh University, LeHigh, PA, ⁵Equillium, La Jolla, CA, ⁶Postgraduate Institute of Medical education and Research, Chandigarh, India
Background/Purpose: Itolizumab is a first-in-class, non-depleting, monoclonal antibody against the co-stimulatory receptor CD6 that blocks its interaction with ALCAM, to inhibit Teff cell activity and…
Abstract Number: 1580 • ACR Convergence 2023
CXCL13+ T Cell Differentiation in Systemic Lupus Erythematosus Is Controlled by Opposing Effects of Aryl Hydrocarbon Receptor and Type I Interferon
Calvin Law¹, Vanessa Wacleche², Ye Cao³, Arundhati Pillai¹, Alice Horisberger⁴, Sabrina Bracero³, Viktoriya Skidanova³, Zhihan Li³, Ifeoluwakiisi Adejoorin², Isaac Benque³, Diana Pena Nunez³, Daimon Simmons², Joshua Keegan⁴, Lin Chen³, John Sowerby³, Accelerating Medicines Partnership (AMP): RA/SLE², Elena Massarotti², Karen Costenbader⁴, Michael Brenner⁴, James Lederer⁴, Judd Hultquist¹, Jaehyuk Choi¹ and Deepak Rao², ¹Northwestern University Feinberg School of Medicine, Chicago, IL, ²Brigham and Women's Hospital, Boston, MA, ³Brigham and Women's Hospital, Boston, MA, ⁴Brigham and Women's Hospital and Harvard Medical School, Boston, MA
Background/Purpose: Expansion of B cell-helper T cells including T follicular helper (Tfh) and T peripheral helper (Tph) cells is a prominent feature of systemic lupus…
Abstract Number: 1652 • ACR Convergence 2023
Lupus Research Action Network: Increasing Minority Clinical Trial Participation Through Peer Leaders
Melicent Miller¹, Stephanie Slan¹, Rosalind Ramsey-Goldman², Rodlescia Sneed³, Candace Feldman⁴, Patrick Wildman¹, Tori Justin⁵, Lydia Oberholtzer⁵ and Joy Buie⁶, ¹Lupus Foundation of America, Washington, DC, ²Northwestern University, Chicago, IL, ³Wayne State University, Detroit, MI, ⁴Brigham and Women's Hospital, Boston, MA, ⁵Sharp Insight, LLC, Montgomery County, MD, ⁶Lupus Foundation of America, York, SC
Background/Purpose: Black/African American people with lupus (PWL) experience greater disease prevalence and severity than White PWL. The need for more racial and ethnic diversity amongst…
Abstract Number: 1859 • ACR Convergence 2023
Examining Hydroxychloroquine Prescribing and SLE Damage in a Statewide Lupus Cohort
Jenna Cormier¹, Bryn Sutherland¹, Yiran Jiang², David Gazeley³, Jonathan Katz⁴, Shalvi Parikh⁴, Carlos Torres⁵, Eden Charles⁵, Ang Yu⁶, Felix Elwert⁶ and Christie M. Bartels⁷, ¹Medical College of Wisconsin, Milwaukee, WI, ²Department of Medicine, Medical College of Wisconsin, Milwaukee, WI, ³Medical College of Wisconsin, Wauwatosa, WI, ⁴Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI, ⁵University of Wisconsin School of Medicine and Public Health, Madison, WI, ⁶Department of Sociology, University of Wisconsin, Madison, WI, ⁷University of Wisconsin, School of Medicine and Public Health, Madison, WI
Background/Purpose: Systemic lupus erythematosus (SLE) is a heterogeneous disease that disproportionately affects women, racially and ethnically minoritized populations, and people of lower socioeconomic status (SES).…
Abstract Number: 2261 • ACR Convergence 2023
Burden of Flare and Organ Damage in Systemic Lupus Erythematosus (SLE) in the Asia Pacific Region: A Multicenter Cohort Study
Rangi Kandane-Rathnayake¹, Dominique Milea², Worawit Louthrenoo³, Alberta Hoi⁴, Vera Golder¹, Jiacai Cho⁵, Aisha Lateef⁵, Shue-Fen Luo⁶, Yeong-Jian J Wu⁷, Laniyati Hamijoyo⁸, Sargunan Sockalingam⁹, Zhanguo Li¹⁰, Sandra Navarra¹¹, Leonid Zamora¹¹, Masayoshi Harigai¹², Yasuhiro Katsumata¹², Madelynn Chan¹³, Yanjie Hao¹⁴, Zhuoli Zhang¹⁵, Sean O’Neill¹⁶, Fiona Goldblatt¹⁷, Shereen Oon¹⁸, Xiaomeng Xu², Aldo Amador Navarro Rojas¹⁹, Sang-Cheol Bae²⁰, Chak Sing Lau²¹, Mandana Nikpour²² and Eric Morand²³, ¹Monash University, Department of Medicine, Sub-faculty of Clinical and Molecular Medicine, Clayton, Australia, ²GlaxoSmithKline, Value Evidence and Outcomes, Singapore, Singapore, ³Chiang Mai University Hospital, Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, Chiang Mai, Thailand, ⁴Monash University, Department of Medicine, Sub-faculty of Clinical and Molecular Medicine, Melbourne, Australia, ⁵National University Hospital, Rheumatology Division, Department of Medicine, Singapore, Singapore, ⁶Chang Gung University, Department of Rheumatology, Allergy and Immunology, Chang Gung Memorial Hospital, Taoyuan, Taiwan, ⁷Chang Gung University, Department of Rheumatology, Allergy and Immunology, Chang Gung Memorial Hospital, Keelung, Taiwan, ⁸Padjadjaran University/Hasan Sadikin General Hospital, Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, Bandung, Indonesia, ⁹University of Malaya, Department of Medicine, Faculty of Medicine Building, Kuala Lumpur, Malaysia, ¹⁰Peking University Health Science Center, Department of Rheumatology and Immunology, People's Hospital, Beijing, China, ¹¹University of Santo Tomas Hospital, Joint and Bone Center, Manila, Philippines, ¹²Tokyo Women's Medical University, Division of Rheumatology, Department of Internal Medicine, Tokyo, Japan, ¹³Tan Tock Seng Hospital, Department of Rheumatology, Allergy & Immunology, Singapore, Singapore, ¹⁴St Vincent’s Hospital Melbourne, Department of Rheumatology, Melbourne, Australia, ¹⁵Peking University First Hospital, Rheumatology and Immunology Department, Beijing, China, ¹⁶Department of Medicine, University of New South Wales, Kensington, Australia, ¹⁷Royal Adelaide Hospital and Flinders Medical Centre, Adelaide, Australia, ¹⁸University of Melbourne at St Vincent’s Hospital, Departments of Rheumatology and Medicine, Fitzroy, Australia, ¹⁹GlaxoSmithKline, Medical Affairs, Singapore, Singapore, ²⁰Hanyang University Hospital for Rheumatic Diseases and Hanyang University Institute for Rheumatology Research, Department of Rheumatology, Seoul, South Korea, ²¹University of Hong Kong, Division of Rheumatology & Clinical Immunology, Department of Medicine, Queen Mary Hospital, Hong Kong, Hong Kong, ²²The University of Melbourne at St. Vincent’s Hospital Melbourne, Departments of Medicine and Rheumatology, Melbourne, Australia, ²³Monash University, Centre for Inflammatory Diseases, Melbourne, Australia
Background/Purpose: Up to 50% of patients with SLE develop irreversible organ damage within 10 years of diagnosis, and most experience recurrent disease flares of varying…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].